First-line treatment for advanced dedifferentiated liposarcoma
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new treatment for advanced dedifferentiated liposarcoma that has not been treated yet. The goal is to see if the treatment can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with dedifferentiated liposarcoma (a type of soft tissue cancer).
- Your cancer is advanced or cannot be removed with surgery, and you have not yet received chemotherapy or other systemic therapy for it.
- Your cancer has not spread to the brain.
- You are in good physical condition (able to carry out daily activities and light work).
- Your major organs (heart, blood, liver, kidneys) are functioning well enough, as checked by blood tests and heart scans.
- If you are able to have children, you must use effective birth control during the study and for 8 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
This trial tests a new drug called bexmarilimab combined with doxorubicin for people with soft-tissue sarcoma that has spread to other parts of the body. The goal is to see if the combination is safe and works better than doxorubicin alone.
This trial tests a treatment made from your own immune cells, called tumor-infiltrating lymphocytes, to see if they can shrink or slow down advanced soft tissue sarcoma. It might be an option if you have tried other treatments and your cancer is still growing.
This study tests a combination of two chemotherapy drugs—utidelone and doxorubicin—for people with advanced soft tissue sarcoma. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
Hear when a new Dedifferentiated Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.